Rallybio Corp (RLYB) Form 10-Q — Oct 27, 2026
Rallybio's Q3 2026 10-Q confirms the pending reverse merger with Avenzo Therapeutics under which Rallybio equityholders would retain only ~2.8% of the combined company (Avenzo holders 56.6%, new financing investors 40.6%), with Rallybio valued at $15.0 million after distributing its pre-closing cash. Holders of pre-merger Rallybio shares will receive one CVR per share covering net proceeds from disposition of legacy assets, including Recursion milestone and royalty payments. A $215.0 million concurrent financing is conditioned on the merger closing, which Rallybio expects before end of 2026.
Key figures
- Eps
- 5.73
- Net Income
- 32662000
- Total Assets
- 95579000
- Cash Position
- 90700000
- Deal Value Usd
- $300.0 million (Avenzo valuation in merger exchange ratio)
- Gross Proceeds
- 215000000
- Shares Outstanding
- 5383937
- Accumulated deficit
- 269336000
- Reverse split ratio
- 1-for-8 (effective Feb 6, 2026)
- Termination fee received
- 50000000
- Avenzo pro forma ownership
- 56.6%
- Operating cash flow 9m 2026
- 35665000
- Rallybio pro forma ownership
- 2.8%
- Rallybio valuation in merger
- $15.0 million (after cash distribution)
- Concurrent financing ownership
- 40.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.